


Serbian Society for Mitochondrial and Free Radical Physiology  
Third Congress

# REDOX MEDICINE

REACTIVE SPECIES SIGNALING, ANALYTICAL METHODS, PHYTOPHARMACY, MOLECULAR MECHANISMS OF DISEASE



Book of Abstracts  
Belgrade, September 25-26, 2015.

**Serbian society for mitochondrial and free-radical physiology**

**BOOK OF ABSTRACTS**

**Third Congress**

**REDOX MEDICINE**

**Reactive Species Signaling, Analytical Methods, Phytopharmacy, Molecular Mechanisms of Disease**

**September 25-26, 2015.  
Belgrade, Serbia**

**SSMFRP-2015**

**Edited by:  
Bato Korać  
Ana Stančić**

**Publishers:**

Serbian society for mitochondrial and free-radical physiology  
Ministry of Education, Science and Technological Development  
University of Belgrade, Faculty of Biology  
University of Belgrade, Institute for biological research “Siniša Stanković”  
University of Belgrade, Faculty of Pharmacy  
University of Belgrade, Faculty of Medicine

**For publishers:**

Bato Korać  
Jelena Knežević-Vukčević  
Vladimir Bumbaširević  
Nada Kovačević  
Zorica Vujić  
Nebojša Lalić

**Editors:**

Bato Korać  
Ana Stančić

**Technical editors:**

Ana Stančić  
Aleksandra Janković

**Design:**

Ana Stančić  
Aleksandra Janković

**Print:** “Alta nova printing house“: 200 copies

Copyright © 2015 by the Serbian society for mitochondrial and free-radical physiology and others contributors. All rights reserved. No part of this publication may be reproduced, in any form or by any means, without permission in writing from the publisher.

**ISBN: 978-86-912893-3-1**

## **ORGANISING AND SCIENTIFIC COMMITTEE**

### **HONORARY PRESIDENT**

**Sir Salvador Moncada, UK**

### **PRESIDENT**

**Bato Korac, Serbia**

### **MEMBERS**

**Marko Andjelkovic, Serbia**  
**Silvana Andric, Serbia**  
**Vladimir Bumbasirevic, Serbia**  
**Biljana Buzadzic, Serbia**  
**Andreas Daiber, Germany**  
**Jerka Dumic, Croatia**  
**Dragan Djuric, Serbia**  
**Milos Filipovic, Germany**  
**Francesco Galli, Italy**  
**Aleksandra Jankovic, Serbia**  
**Tomas Jelenik, Germany**  
**Elena Kistanova, Bulgaria**  
**Selma Kanazir, Serbia**  
**Jelena Knezevic-Vukcevic, Serbia**  
**Aleksandra Korac, Serbia**  
**Tatjana Kostic, Serbia**  
**Jelena Kotur-Stevuljevic, Serbia**  
**Nada Kovacevic, Serbia**  
**Radmila Kovacevic, Serbia**  
**Nebojsa Lalic, Serbia**  
**Danijela Maksimovic-Ivanic, Serbia**  
**Janja Marc, Slovenia**  
**Snezana Markovic, Serbia**  
**Sanja Mijatovic, Serbia**  
**Tomas Mracek, Czech Republic**  
**Vesna Niketic, Serbia**  
**Branka Ognjanovic, Serbia**  
**Vesna Otasevic, Serbia**  
**Snezana Pajovic, Serbia**  
**Dusica Pavlovic, Serbia**  
**Michail Rallis, Greece**  
**Zorica Saicic, Serbia**  
**Ana Savic-Radojevic, Serbia**  
**Tatjana Simic, Serbia**  
**Mihajlo Spasic, Serbia**

**Slavica Spasic, Serbia**  
**Ana Stancic, Serbia**  
**Milena Stevanovic, Serbia**  
**Ivana Stojanovic, Serbia**  
**Zeljko Tomanovic, Serbia**  
**Fulvio Ursini, Italy**  
**Zorica Vujic, Serbia**

P50

## SYNERGISTIC ANTICANCER ACTION OF LYSOSOMAL MEMBRANE PERMEABILIZATION AND GLYCOLYSIS INHIBITION

Milica Kosic<sup>1</sup>, Katarina Arsikin-Csordas<sup>1</sup>, Verica Paunovic<sup>1</sup>, Raymond A. Firestone<sup>2</sup>, Biljana Ristic<sup>1</sup>, Aleksandar Mirčić<sup>3</sup>, Saša Petričević<sup>4</sup>, Mihajlo Bošnjak<sup>3</sup>, Nevena Zogović<sup>5</sup>, Vladimir Bumbaširević<sup>3</sup>, Vladimir Trajković<sup>1</sup>, Ljubica Harhaji-Trajković<sup>5</sup>

<sup>1</sup>*Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, Belgrade, Serbia*

<sup>2</sup>*30 West 72 St., Apartment 10A, New York, NY 10023*

<sup>3</sup>*Institute of Histology and Embryology, School of Medicine, University of Belgrade, Belgrade, Serbia*

<sup>4</sup>*Institute of Biomedical Research, Galenika a.d., Belgrade, Serbia*

<sup>5</sup>*Institute for Biological Research, University of Belgrade, Belgrade, Belgrade, Serbia*

We investigated the *in vitro* anticancer effect of combining lysosomal membrane permeabilization (LMP)-inducing agent N-dodecylimidazole (NDI) with glycolytic inhibitor 2-deoxy-D-glucose (2DG). Cell viability was measured by MTT and LDH tests. Oxidative stress, lysosomal permeabilization, mitochondrial depolarization and apoptosis/necrosis were analyzed by flow cytometry. Cell morphology was examined by electron microscopy. Intracellular ATP content was measured by bioluminescence assay. NDI-triggered LMP and 2DG-mediated glycolysis block synergized in inducing rapid ATP depletion, mitochondrial damage, and reactive oxygen species (ROS) production, eventually leading to necrotic death of U251 glioma cells, but not primary astrocytes. NDI/2DG-induced death of glioma cells was partly prevented by lysosomal cathepsin inhibitor E64 and antioxidant  $\alpha$ -tocopherol, indicating the involvement of LMP and oxidative stress in the observed cytotoxicity. LMP-inducing agents chloroquine and NH<sub>4</sub>Cl also displayed synergistic anticancer effect with 2DG, while glycolytic inhibitors iodoacetate and sodium fluoride synergistically cooperated with NDI, thus confirming that the anticancer effect of NDI/2DG combination was indeed due to LMP and glycolysis block, respectively. Based on these results, we propose that NDI-triggered LMP causes initial mitochondrial damage that is further increased by 2DG due to the lack of glycolytic ATP required to maintain mitochondrial health. This leads to a positive feedback cycle of mitochondrial dysfunction, ATP loss, and ROS production, culminating in necrotic cell death. Therefore, the combination of LMP-inducing agents and glycolysis inhibitors seems worthy of further exploration as an anticancer strategy.